FindTrial
Sign In

Comparison of survival outcomes between neoadjuvant and adjuvant therapy in patients with T1c, lymph node-negative, and hormone receptor-negative breast cancer: a study based on the SEER database and a Chinese cohort

Comparison of survival outcomes between neoadjuvant and adjuvant therapy in patients with T1c, lymph node-negative, and hormone receptor-negative breast cancer: a study based on the SEER database and a Chinese cohort

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115125
Enrollment
Unknown
Registered
2025-12-23
Start date
2025-12-31
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Case series :none

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Female; 2. Diagnosed between 2010 and 2020; 3. Pathologically confirmed as stage T1cN0M0, hormone receptor (HR)-negative; 4. Single primary tumor site.

Exclusion criteria

Exclusion criteria: 1. Age > 80 years; 2. No chemotherapy or surgery received; 3. Insufficient key information or uncertain response to neoadjuvant therapy (NAT).

Design outcomes

Primary

MeasureTime frame
Overall Survival;Breast Cancer-Specific Survival;—

Secondary

MeasureTime frame
Pathological Complete Response;—

Countries

China

Contacts

Public ContactJie Chen

West China Hospital of Sichuan University

chenjiewestchina@163.com+86 189 8060 6313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026